You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中恆集團受新版醫保目錄影響預計明年血栓通銷量將下降15%-25%
格隆匯 08-21 19:24
格隆匯8月21日丨中恆集團公告,國家新版醫保目錄調整內容包含了公司的產品注射用血栓通(凍幹)、血栓通注射液。目前注射用血栓通(凍幹)、血栓通注射液主要用於瘀血阻絡、中風偏癱、胸痺心痛及視網膜中央靜脈阻塞症,此次醫保目錄報銷範圍減去了瘀血阻絡、胸痺心痛兩個適應症。由於本次醫保目錄將於2020年1月1日正式實行,預計本年度對公司血栓通銷售影響較小,預計2020年血栓通銷量將會下降15%-25%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account